← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Glsynthesis, Inc.
Worcester, MA
$28,782,344
Total funding
29
Grants
Funding over time
peak $3.1M · FY2005–16$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$28,782,344 · 29
By mechanism
R44$24,602,536 · 13
R43$3,859,342 · 15
R41$320,466 · 1
Investigators at Glsynthesis, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Non-Sedating Atropisomeric Drugs for Atopic Diseases$1,554,089
R44 · FY2007 · GM
Novel Antithrombotic Diadenosine Tetraphosphate Analogs$1,417,233
R44 · FY2015 · TR
Preclinical development of a novel antibacterial for Clostridium difficile diseas$1,415,514
R44 · FY2012 · AI
Novel Antithrombotic Diadenosine Tetraphosphate Analogs$1,120,723
R44 · FY2013 · TR
Non-Sedating Atropisomeric Drugs for Atopic Diseases$1,042,236
R44 · FY2006 · GM
New Dermal Anesthetics$1,010,101
R44 · FY2002 · AR
Hybrid Molecules Designed to Enhance Antibiotic Activity$967,036
R44 · FY2008 · AI
DNA Polymerase IIIe, A New Antibiotic Target$944,079
R44 · FY2005 · AI
Hybrid Molecules Designed to Enhance Antibiotic Activity$939,605
R44 · FY2007 · AI
Hybrid Molecules Designed to Enhance Antibiotic Activity$938,275
R44 · FY2006 · AI
Preclinical development of a novel antibacterial for Clostridium difficile diseas$935,484
R44 · FY2011 · AI
DNA Polymerase IIIe, A New Antibiotic Target$907,102
R44 · FY2006 · AI
Novel Drugs to Treat Urinary Incontinence$894,091
R44 · FY2009 · AG
Novel Antithrombotic Diadenosine Tetraphosphate Analogs$858,985
R44 · FY2014 · TR
Novel Drugs to Treat Urinary Incontinence$794,658
R44 · FY2008 · AG
Novel Antithrombotic Diadenosine Tetraphosphate Analogs$779,748
R44 · FY2010 · HL
Novel Antithrombotic Diadenosine Tetraphosphate Analogs$768,369
R44 · FY2009 · HL
New Dermal Anesthetics$763,177
R44 · FY2003 · AR
Preclinical development of a novel antibacterial for Clostridium difficile diseas$620,114
R44 · FY2010 · AI
Development of a fluorescence ABCG2 liposomal multidrug transporter assay$597,909
R44 · FY2016 · GM